01 Shift toward Proactive Hemoglobin Monitoring During Chemotherapy The chemotherapy-induced anemia market analysis shows a shift toward proactive hemoglobin monitoring to identify declining hemoglobin levels and manage anemia before it significantly affects patients' health. Regular blood tests help oncology teams assess anemia severity, monitor changes during chemotherapy cycles, and determine the need for supportive treatments such as iron supplementation, erythropoiesis-stimulating agents, or red blood cell transfusions.
02 Integration of Biomarker-based Risk Assessment in Anemia Management Integration of biomarker-based risk assessment is shaping the chemotherapy-induced anemia market by helping healthcare professionals identify factors contributing to reduced red blood cell production during cancer treatment. Indicators such as ferritin, transferrin saturation, and inflammatory markers can help distinguish iron deficiency from inflammation-related anemia and guide appropriate treatment decisions.
01 Supply chain disruptions are expected to have a moderate impact on the chemotherapy-induced anemia market share due to dependence on active pharmaceutical ingredients, iron preparations, and erythropoiesis-stimulating agents. The market is expected to follow a stair-step recovery, as shortages of pharmaceutical ingredients, manufacturing delays, and distribution constraints can affect the availability of anemia treatments. The market is expected to grow at a CAGR of 5.60%, but supply chain constraints could lower this by 0.7 percentage points, resulting in a growth of around 4.90%. As supply conditions normalize, the chemotherapy-induced anemia market growth is expected to gradually return to 5.60%.
01 The chemotherapy-induced anemia market forecasts strategic investment activity driven by the development of novel anemia therapies and research into treatments that improve red blood cell production and iron utilization. In April 2026, Ferrosa Therapeutics secured seed financing of USD 3.5 million led by Forty51 Ventures to develop a bispecific antibody targeting anemia of inflammation associated with cancer, chronic kidney disease, and autoimmune diseases.
01 Demand for Effective Management of Chemotherapy-Related Anemia and Adoption of Combination Cancer Therapies Drive Market Chemotherapy can reduce red blood cell production and cause anemia, leading to fatigue, weakness, and reduced physical functioning in cancer patients. The need to manage these complications is increasing the use of treatments such as erythropoiesis-stimulating agents and iron supplementation, contributing to chemotherapy-induced anemia market growth. Dependence on combination cancer therapies can increase the risk of treatment-related complications, including anemia, depending on the drugs and treatment regimens involved. This creates a greater need for hemoglobin monitoring and supportive care throughout cancer treatment. The focus on managing these adverse effects while maintaining appropriate treatment schedules supports demand for chemotherapy-induced anemia management options.
01 Risk of Adverse Effects from Erythropoiesis-Stimulating Agents and Need for Frequent Hemoglobin Monitoring Restrain Market Expansion Erythropoiesis-stimulating agents (ESAs) used to manage chemotherapy-induced anemia can cause adverse effects, including an increased risk of thromboembolic events and hypertension. These risks require careful patient selection, appropriate dosing, and regular assessment of treatment response. Safety concerns and restrictions on ESA use in certain cancer treatment settings may limit their suitability for some patients, creating challenges for wider adoption and restraining market growth.Managing chemotherapy-induced anemia requires regular hemoglobin monitoring to assess anemia severity, evaluate treatment response, and determine the need for interventions such as iron supplementation, ESAs, or red blood cell transfusions. Hemoglobin levels can fluctuate depending on chemotherapy regimens, cancer progression, and individual patient responses.
01 Expansion of Iron Management Solutions for Cancer Patients and Digital Tools for Anemia Care Coordination Offers Growth Opportunities Pharmaceutical companies and diagnostic providers can target oncology care centers managing anemia associated with chemotherapy and related iron deficiencies. Iron assessment and replacement solutions can help clinicians identify patients who may benefit from iron supplementation as part of their anemia management plan. Revenue opportunities include iron-based therapies, diagnostic testing services, and supply agreements with cancer treatment facilities, contributing to chemotherapy-induced anemia market growth.Healthcare technology providers can target oncology clinics seeking to coordinate anemia assessments, treatment schedules, and follow-up care throughout chemotherapy. Digital platforms can help care teams organize hemoglobin results, track treatment-related symptoms, and identify patients requiring further evaluation. Market players can bank on new revenue avenues through software subscriptions, clinical workflow solutions, and service contracts with healthcare networks.